In-hospital and out-of-hospital NO portable pulse inhaler

The home NO portable pulse inhaler was developed by IKARIA. IKARIA is the only FDA-approved manufacturer of hospital-use NO (nitric oxide) inhalers for the treatment of pulmonary hypertension in newborns (PPHN) in the United States. IKARIA was acquired by Mallinckrodt in 2015 for $2.3 billion, and Bellerophon was spun off and continue develop the INOpulse system for home use, which has been tested over time to be safe, stable, lightweight and easy to operate to meet portable requirements.

Baylor Biosciences will develop, manufacture, and commercialize the product in Great China. The product can be used in hospitals for acute NO treatment, as well as for patients who need to carry NO treatment for a long time. The unique assembly method and safety of the product will facilitate the use of NO in medical treatment and make it easy for patients to carry it with them.

Currently, INOpulse is in Phase III clinical trial for pulmonary fibrosis pulmonary hypertension (PH-PF), has completed Phase II clinical trial for chronic obstructive pulmonary hypertension (PH-COPD), and is in Phase II clinical trials for pulmonary hypertension in nodular disease (PH-SA).